Formulation and Evaluation of Pyrazinamide loaded Pegylated Polypropylene imine dendrimer for treating Tuberculosis

Author: Valli Manalan B., Arul B. and Kothai R.

Download PDF

Abstract

The purpose of the contemporary research was to construct a Pyrazinamide loaded PEGylated fifth generation (5.0G) Poly (Propylene)-Imine (PPI) dendrimer for the treatment of tuberculosis. A PEGylated poly(propylene-imine) dendrimer was prepared, and the drug pyrazinamide was loaded. Tuberculosis is a deadly contagious disease that affects the respiratory systems of the human. Pyrazinamide (PZA) is used to treat Tuberculosis (TB). The dendrimers exhibit superior performance in the process of targeted drug delivery. It increases the drug loading capacity and minimises haemolytic toxicity. The physical as well as chemical properties of the drugs are analysed through UV-spectrophotometric analysis. The free 5.0G PPI dendrimer, synthesis pyrazinamide loaded PEGylated fifth-generation PPI- dendrimer and PEGylated 5.0G PPI dendrimer are considered subjects of enhancing the drug loading capacity investigation. Several research findings have revealed that PEGylation is suitable for modifying the core Ethylene Diamine (EDA)-PPI dendrimers of ethylene diamine initiator. In this work, the transportation of the drug will be carried out at a controlled rate, thereby increasing therapeutic value and minimising fluctuations in plasma concentration. This feature helps to improve the therapeutic intervention in the patients affected by TB.

Keywords

Pyrazinamide, Ethylene diamine, PPI dendrimers, PEGylation, drug delivery

Conclusion

Dendrimers emerge as an excellent drug carrier, preferred for treating TB. Among the classes of dendrimers, PPI dendrimer remains the most recognised one. In addition to it, dendrimers can improve drug efficiency (Scicluna et al., 2020). Hence, this research utilised the pyrazinamide drug for treating tuberculosis and loaded it into the PPI dendrimer to enhance its efficacy and control the drug release rate. The PEGylation is discovered as the appropriate surface modification technique to enhance the controlled release of the drug in 5.0G PPI dendrimer. The study utilises the EDA as the originator core for producing 5.0G PPI dendrimer and finally encumbered the Pyrazinamide. Hence, the Pyrazinamide loaded. PEGylated 5.0 G PPI exhibits controlled drug release for a long time compared to the free fifth-generation PPI and PEGylated PPI dendrimer. Also, the study conducted in vitro drug release analysis and release kinetic and stability experiments revealed that the prepared Pyrazinamide loaded PEGylated 5.0 G PPI regulates the drug release for a prolonged time and minimises the variation in plasma drug concentration. This novel approach enhances drug therapy management in TB patients and reduces the treatment time.

References

-

How to cite this article

Valli Manalan. B., Arul. B. and Kothai, R. (2023). Formulation and evaluation of Pyrazinamide loaded pegylated polypropylene imine dendrimer for treating tuberculosis. Biological Forum – An International Journal, 15(6): 768-776.